Medytox Solutions Announces Results For The Year Ended December 31, 2014

WEST PALM BEACH, FL--(Marketwired - April 15, 2015) -

Highlighted Links

LinkedIn

Medytox Solutions, Inc.

Medytox Solutions, Inc. (OTCQB: MMMS) announced today its financial results for the year ended December 31, 2014 (the "2014 Year"). The Company reported net revenues of approximately $57.9 million, which represented an increase of approximately $16 million, or 38%, from the approximately $41.9 million in net revenues reported for the year ended December 31, 2013 (the "2013 Year"). For the 2014 Year, the Company reported income from operations of approximately $15.7 million, compared to income from operations of approximately $14.5 million for the 2013 Year.

"Our 2014 results demonstrate a continued growth in revenue and earnings as a direct result of our investment in and commitment from an expanding and strong workforce and the demand for the Company's products and services in the healthcare sector," stated Seamus Lagan, the Company's Chief Executive Officer.

About Medytox Solutions, Inc.

Medytox Solutions, Inc. is a holding company that owns and operates businesses in the medical services sector. Medytox is a new generation healthcare enterprise that delivers a single source for integrated solutions. Medytox applies its innovative approach through an outstanding suite of IT & software solutions, revenue cycle management and financial services, combined with a range of diagnostic testing and other ancillary services for the healthcare sector. Its principal line of business is clinical laboratory blood and urine testing services, with a particular emphasis in the provision of urine drug toxicology testing to physicians, clinics and rehabilitation facilities in the United States.

                                                                            
                   MEDYTOX SOLUTIONS, INC. & SUBSIDIARIES                   
                    Consolidated Statements of Operations                   
                                                                            
                                               For the Year Ended December  
                                                            31,             
                                              ----------------------------- 
                                                   2014            2013     
                                              --------------  ------------- 
                                                                            
Revenues                                                                    
    Gross charges (net of contractual                                       
     allowances and discounts)                $   77,223,964  $  52,523,660 
    Provision for bad debts                      (19,296,144)   (10,634,789)
                                              --------------  ------------- 
    Net Revenues                              $   57,927,820  $  41,888,871 
                                                                            
Operating expenses:                                                         
  Direct costs of revenue                         15,920,468      9,570,950 
  General and administrative                      19,712,018     13,479,879 
  Legal fees related to disputed subsidiary           94,217        976,789 
  Sales and marketing expenses                     4,967,188      2,953,292 
  Bad debt expense                                    78,482              - 
  Depreciation and amortization                    1,500,453        407,971 
                                              --------------  ------------- 
    Total operating expenses                      42,272,826     27,388,881 
                                                                            
Income from operations                            15,654,994     14,499,990 
                                                                            
Other income (expense):                                                     
  Other income                                           489            389 
  Gain (Loss) on settlement of assets                      -        (27,413)
  Gain on disposition of subsidiary                  134,184              - 
  Gain (Loss) on legal settlement                    105,780       (169,800)
  Interest expense                                  (513,815)      (474,649)
                                              --------------  ------------- 
    Total other income (expense)                    (273,362)      (671,473)
                                              --------------  ------------- 
                                                                            
Income before income taxes                        15,381,632     13,828,517 
                                                                            
  Provision for income taxes                       7,561,300      5,568,600 
                                              --------------  ------------- 
                                                                            
Net income attributable to Medytox Solutions       7,820,332      8,259,917 
                                                                            
  Preferred stock dividends                        5,010,300      2,601,298 
                                              --------------  ------------- 
                                                                            
Net income attributable to Medytox Solutions                                
 common shareholders                          $    2,810,032  $   5,658,619 
                                              ==============  ============= 
                                                                            
Net income per common share:                                                
  Basic                                       $         0.09  $        0.19 
                                              ==============  ============= 
  Diluted                                     $         0.09  $        0.19 
                                              ==============  ============= 
                                                                            
Weighted average number of common shares                                    
 outstanding during the period:                                             
  Basic                                           29,899,536     29,692,110 
                                              ==============  ============= 
  Diluted                                         30,924,538     30,160,335 
                                              ==============  ============= 
                                                                            

"Forward-looking" Statements

This press release may contain "forward-looking statements," as defined in the Private Securities Litigation Reform Act of 1995, as amended. Any such statements are made pursuant to the safe-harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, and they involve a number of risks and uncertainties that could cause actual results to differ materially from those that may be anticipated by or from the forward-looking statements. Important factors that could cause such a difference are set forth in the Company's filings with the Securities and Exchange Commission and include, but are not limited to, the ability to consummate acquisitions and the ability to integrate such acquisitions.